Paradoxical Emboli from Calf and Pelvic Veins in Cryptogenic Stroke

Permalink
https://escholarship.org/uc/item/70x2n594

Journal
Journal of Neuroimaging, 13(3)

ISSN
1051-2284

Authors
Cramer, Steven C
Maki, Jeffrey H
Waitches, Gayle M
et al.

Publication Date
2003-07-01

DOI
10.1111/j.1552-6569.2003.tb00181.x

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
ABSTRACT

Purpose. The increased prevalence of patent foramen ovale in patients with cryptogenic strokes suggests the occurrence of paradoxical embolism. The identification of deep venous thromboses (DVTs) in this population would strengthen this hypothesis. The purpose of this study was to image the subdiaphragmatic venous system in a cohort of patients with cryptogenic strokes. Materials and Methods. In 37 patients with cryptogenic brain ischemia and interatrial communication, duplex studies of calf, popliteal, and femoral veins, and magnetic resonance imaging venograms of the pelvis veins were performed. Results. In 10 patients, DVTs were diagnosed that were considered to be the cause of cryptogenic brain ischemia on probable (n = 6) or possible (n = 4) bases. In these patients, the median time from stroke to DVT was 3.25 days. In 5 of these 10 patients, DVTs did not involve popliteal and femoral veins, areas thought most important to pulmonary embolism, but instead were isolated to calf or pelvic veins. Although none of these 10 patients had abnormal blood hypercoagulation tests, 8 of the 10 did have clinical conditions suggesting predisposition to developing DVTs, such as concomitant neoplasms or pulmonary embolism. Conclusions. Increased evidence for paradoxical embolism may emerge when diagnostic strategies use multiple imaging methods and evaluate a broad extent of the subdiaphragmatic veins.

Key words: Cryptogenic stroke, paradoxical embolism, deep venous thrombosis, patent foramen ovale.
Patients with strokes of determined origins or in normal controls. The risk for PFO-related stroke is further increased when an atrial septal aneurysm is also present, though the presence of an atrial septal aneurysm may in part be a reflection of larger PFO size.

Cryptogenic stroke in the presence of an interatrial shunt is a common clinical scenario, but the fraction of cryptogenic strokes accounted for by paradoxical embolisms remains uncertain because a venous source of embolic material has not been identified. The increased detection of deep venous thromboses (DVTs) in patients with cryptogenic strokes and PFOs might be achieved by using multiple diagnostic modalities and by evaluating all subdiaphragmatic veins. The current study reports the results of combined duplex and magnetic resonance imaging (MRI) evaluation of the subdiaphragmatic venous system in a cohort of 37 patients with cryptogenic brain ischemic events plus right-to-left intracardiac communication.

Patients and Methods

During the service time of 2 physicians (SCC, WSB), a venous system study was performed as part of clinical evaluation in 37 patients with interatrial shunts and cryptogenic brain ischemic events. Events were labeled cryptogenic only after the normal evaluation of extracranial and intracranial arteries and echocardiography. Of the 37 patients, 6 were from the University of Texas, Houston (UT), and 31 were from the University of Washington (UW). The mean (±SD) age was 54 ± 16 years (range, 22-80 years). There were 25 female and 12 male patients. Articular studies used Doppler methods in 19 patients, magnetic resonance angiograms in 7, catheter angiograms in 5, and 2 or more of these methods in 6. Echocardiograms were transesophageal in 20 patients and transthoracic in 17 patients. PFOs were present in 35 patients, 5 of whom had concomitant atrial septal aneurysms, while 2 patients had atrial septal defects (ASDs).

Among these 37 patients, the median time from cerebral ischemic event to the first study of the venous system was 8 days. At the time of venous system evaluation, 23 patients were receiving antplatelet agents, 9 were receiving anticoagulation, 2 were receiving both, 1 was < 24 hours after intravenous tissue plasminogen activator, and 2 were receiving no treatments related to thromboses. There were 22 inpatients and 15 outpatients. Brain ischemia was transient ischemic attacks in 6 patients and strokes in 31.

Venous system evaluation included leg vein duplex and pelvic vein magnetic resonance venography (MRV). Venous duplex exams included the evaluation of the bilateral deep femoral, superficial femoral, and popliteal veins. At UW, duplex exams also included the tibial, saphenous, and peroneal veins.

Pelvic MRV included time-of-flight (TOF) and phase-contrast (PC) imaging using a torso coil at 1.5 T, without the introduction of contrast. The field of view extended from the infrarenal inferior vena cava to the proximal common femoral vein. For TOF images, slices were 3 mm thick with 2-mm skips between slices. For PC images, slices were 5 mm thick with no skips and were in plane with TOF slices.

Pelvic MRV images were reviewed by 2 radiologists specializing in abdominal-pelvic imaging who were blinded to all patient clinical data. The final read for the study was either positive or negative for acute pelvic DVT, on the basis of consensus opinion. MRV was deemed positive for acute DVT when both radiologists identified a 15-mm or longer intravascular decrease in signal intensity on TOF images that contacted the wall of the vein. The intravascular signal decrease on PC images was required to match the TOF abnormality.

A paradoxical embolism was considered to be the cause on a probable basis when 2 criteria were met: (1) DVT was documented < 4 days after or up to 1 week prior to the cerebral ischemic insult, and (2) a PFO or an ASD was demonstrated on echocardiogram. Four days poststroke was chosen in defining probable paradoxical embolism because the incidence of poststroke DVT rises significantly after this time. A paradoxical embolism was considered as being the possible cause of the cryptogenic brain ischemic event when a PFO or an ASD was present, and many features were suggestive of a paradoxical embolism, but the first criterion was not completely met. An acute DVT was excluded from either category if diagnosed ≥ 4 days poststroke in a patient with hemiplegia.

Results

A total of 14 of 37 patients were diagnosed with DVTs. Five of these were in the pelvic veins, including 1 patient from UT, and 9 of these were in the leg veins, including 1 patient from UT. In 4 of these 14 patients, the DVTs were determined to be consequences of strokes because of either hemiplegia, DVTs arising after normal poststroke leg duplex exams, or the chronic appearance of DVTs when imaged early after stroke. In the other 10 of these 14 patients, paradoxical embolisms were determined to be the cause of cryptogenic brain ischemia on probable or possible bases. Note that MRV was not performed in 7 of 37 patients for a number of reasons, including MRI availability, claustrophobia, or the diagnosis of calf DVTs.
Among the 10 patients with possible or probable paradoxical embolisms (Table 1 and Fig 1), the mean age was 55 ± 17 years (range, 27-78 years), and the median time from stroke to DVT diagnosis was 3.25 days. There were 5 female and 5 male patients. At the time of venous system evaluation, 5 were receiving antiplatelet agents, 3 were receiving anticoagulation, 1 was receiving both, and 1 was receiving no treatments related to thrombosis. Note that the DVTs in 5 of 10 patients were restricted to calf or pelvic veins. No blood hypercoagulable tests were abnormal in these 10 patients, including negative results on testing IgG and IgM anticardiolipin antibody in 6 patients, activated protein C resistance in 5, protein S in 7, protein C in 6, and antithrombin III in 6; lab error, the early initiation of warfarin, and other factors prevented complete testing in some patients. However, hypercoagulable states were suggested in 8 of 10 patients’ histories: prior (2) or concurrent (1) pulmonary embolism, prior leg DVT, essential thrombocytosis, rectal adenocarcinoma, melanoma, and smoking while taking birth control pills.

In 3 patients, only TOF imaging was performed; in none of these were images suggestive of possible or probable paradoxical embolisms. In 6 patients, the same field of view was covered by a larger number of thinner MRI...
slides because of a technical error. Of these 6 patients, 1 was considered to have a possible, and none a probable, paradoxical embolism.

Discussion

The majority of patients with cryptogenic strokes also have PFOs, suggesting paradoxical embolisms as the basis of the strokes in some patients. However, a venous source of thrombus has infrequently been identified, calling into question whether PFOs are truly relevant to the genesis of strokes. The current study identified 10 patients with cryptogenic brain ischemia plus right-to-left intracardiac communication in whom DVTs were possibly or probably the origin of paradoxical embolisms. Importantly, half of these 10 DVTs were restricted to calf or pelvic veins; that is, they did not involve popliteal or femoral veins.

The prevalence of DVTs among patients with cryptogenic strokes and interatrial shunts is unclear because most previous studies did not consistently examine all subdiaphragmatic veins or were not restricted to cryptogenic strokes. In studies of stroke patients with PFOs but not restricted to cryptogenic strokes, DVTs were found in 6% of an unspecified subset, 5 of 53 patients (9.5%) with suspected cardioemboli, and 19 of 35 patients (54.3%) with cerebral emboli and in many cases known causes of strokes. In 2 studies restricted to patients with cryptogenic strokes, DVTs were found in 3 of 23 (13%) and 1 of 14 (7%) patients with PFOs. The latter 4 studies each used bilateral contrast venography, which may be less sensitive to DVTs in the pelvis as compared to other sites.

Pelvic veins may be an important and under-appreciated source of thromboemboli. At autopsy, the pelvic veins were the only source of paradoxical emboli in 19 of 86 patients (22%) in whom sources could be found, and isolated pelvic DVTs were found in 16% of patients with pulmonary emboli. In 769 consecutive MRV studies of the entire leg and pelvis, found that DVTs isolated to the pelvic veins were more common than in the calf veins and almost as common as in the thigh veins. Other evaluation techniques may have reduced diagnostic sensitivity for pelvic DVTs. Two prior studies found MRV useful for the diagnosis of pelvic DVTs in patients with strokes and interatrial communication.

Calf veins may also be an important source of thromboemboli in the setting of cryptogenic stroke. Isolated calf vein DVTs are more common than DVTs in any other site following stroke and at autopsy. Proximal propagation may occur in 20% to 28% of calf vein DVTs. Embolization can occur without propagation; for example, isolated calf DVTs were found at autopsy in 36% to 46% of patients with pulmonary embolisms. In general medical practice, calf vein thrombi are associated with small emboli, any consequent pulmonary emboli tend to be small and asymptomatic, and these DVTs are therefore considered low risk for important pulmonary events. As a result, anticoagulation is initiated only if repeat testing shows proximal extension. However, small thrombi that are associated with minor injuries to the lung might have important effects on reaching cerebral arteries with diameters of 1 mm. Therefore, the
response to an isolated calf vein DVT may need to be modified when there is significant risk for the transmission of embolic material to the cerebral arterial circulation.

Several features of the study generate caution when generalizing to all patients with cryptogenic strokes. Most patients in whom paradoxical embolisms were suspected (Table 1) had diagnoses suggesting hypercoaguable conditions, which are not likely the case in most stroke populations. This may have been due in part to the high rate of neoplastic diseases among patients seen at UW. In most cases, the sizes of the interatrial shunts were not measured. Such data might have provided greater insight into stroke pathogenesis in patients with and without DVTs. Moreover, the methods used to diagnosis the presence of interatrial shunts may not have been optimal for the most accurate measurement of shunt size.42

The current study identified 10 patients whose cryptogenic strokes arose from paradoxical embolisms on possible or probable bases. Unlike reports for pulmonary embolism,38,40 isolated DVTs in the calf and pelvic veins accounted for 50% of all patients, supporting the utility of a broad assessment of subdiaphragmatic veins in the setting of cryptogenic strokes and interatrial shunts. Sensitivity for DVTs may be improved by use of more than one diagnostic technique. Prospective studies are needed to better define the true prevalence of subdiaphragmatic DVTs acutely after stroke.

We thank Kari Olmsted and Gerardo Ortiz for their assistance in preparing Figure 1.

References

1. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989;25:382-390.
2. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparin, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke. J Am Med Assoc 1998;279:1265-1272.
3. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451.
4. Cabanes L, Mas JL, Cohen A, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993;24:1865-1873.
5. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000;55:1172-1179.
6. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992;117:461-465.
7. Jeurisma X, Bogousslavsky J, Payot M, Regli F, Kappenberger L. Patent foramen ovale and cerebral infarct in young patients. Schweiz Med Wochenshr 1990;120:823-829.
8. Lechat P, Mas JL, Lascault G. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-1152.
9. Steiner MM, Di Tullio MR, Rundek T, et al. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 1998;29:944-948.
10. Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet 1988;1988:11-12.
11. Petty GW, Khandheria BK, Chu C-P, Sicks JD, Whisnant JP. Patent foramen ovale in patients with cerebral infarction. Arch Neurol 1997;54:819-822.
12. Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li Mandri G, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke 1994;25:582-586.
13. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001;38:613-623.
14. Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 2000;109:456-462.
15. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-1746.
16. Schuchlenz HW, Saurer G, Weihs W. Patent foramen ovale, atrial septal aneurysm, and recurrent stroke. N Engl J Med 2002;346:1331-1332.
17. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Br Med J 1976;1:1178-1183.
18. Falk RH. PFO or UFO? The role of a patent foramen ovale in cryptogenic stroke. Am Heart J 1991;121:1264-1266.
19. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebisher N, Van Melle G, the Lausanne Stroke with Paradoxical Embolism Study Group. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Neurology 1996;46:1301-1305.
20. Lethen H, Flachskaempf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 1997;80:1066-1069.
21. Stollberger C, Slany J, Schuster I, Leitner H, Winkler WB, Karnik R. The prevalence of deep vein thrombosis in patients with suspected paradoxical embolism. Am Intern Med 1993;119:461-465.
22. Gauiter JC, Durr A, Koussa S, Lasault G, Grosgeorge T. Paradoxical cerebral embolism with a patent foramen ovale. Cerebrovas Dis 1991;1:193-202.
23. Ranoux D, Cohen A, Cabanes L, Amarencio P, Bousser MG, Mas JL. Patent foramen ovale: is stroke due to paradoxical embolism? Stroke 1993;24:31-34.
24. Bergqvist D, Bergents S E. Diagnosis of deep vein thrombosis. World J Surg 1990;14:679-687.
25. Wheeler HB, Anderson FA. Diagnostic methods for deep vein thrombosis. *Haemostasis* 1995;25:6-26.
26. Corrin B. Paradoxical embolism. *Br Heart J* 1964;26:549-553.
27. Johnson BI. Paradoxical emboli. *J Clin Pathol* 1951;4:316-332.
28. Modan B, Sharon E, Jelin N. Factors contributing to the incorrect diagnosis of pulmonary embolic disease. *Chest* 1972;62:388-393.
29. Spritzer CE, Arata MA, Freed KS. Isolated pelvic deep venous thrombosis: relative frequency as detected with MR imaging. *Radiology* 2001;219:521-525.
30. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. *Stroke* 2001;32:262-267.
31. Cramer SC, Rordorf G, Kaufman JA, Buonanno F, Koroshetz WJ, Schwamm L. Clinically occult pelvic-vein thrombosis in cryptogenic stroke. *Lancet* 1998;351:1927-1928.
32. Greer DM, Buonanno FS. Cerebral infarction in conjunction with patent foramen ovale and May-Thurner syndrome. *J Neuroimaging* 2001;11:432-434.
33. Landi G, D'Angelo A, Boccardi E, et al. Venous thromboembolism in acute stroke: prognostic importance of hypercoagulability. *Arch Neurol* 1992;49:279-283.
34. Havig O. Deep vein thrombosis. *Acta Chirurgica Scandinavica* 1977;478(suppl):4-11.
35. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in sheep’s clothing? *Arch Intern Med* 1988;148:2131-2138.
36. Lohr JM, James KV, Deshmukh RM, Hasselfeld KA. Allastair B. Karmody Award. Calf vein thrombi are not a benign finding. *Am J Surg* 1995;170:86-90.
37. Havig O. Source of pulmonary emboli. *Acta Chirurgica Scandinavica* 1977;478(suppl):42-47.
38. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis [in consultation with the Council on Cardiovascular Radiology], American Heart Association. *Circulation* 1996;93:2212-2245.
39. Salzman EW. Venous thrombosis made easy. *N Engl J Med* 1986;314:847-848.
40. Keanon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. *Ann Intern Med* 1998;129:1044-1049.
41. Mohr JP. Cryptogenic stroke. *New Engl J Med* 1988;318:1197-1198.
42. Schuchlenz HW, Weish W, Beitzke A, Stein JL, Gamillscheg A, Rehak P. Transesophageal echocardiography for quantifying size of patent foramen ovale in patients with cryptogenic cerebrovascular events. *Stroke* 2002;33:293-296.